In a stun­ning turn­around, Bio­gen says that ad­u­canum­ab does work for Alzheimer's — but da­ta min­ing in­cites con­tro­ver­sy and ques­tions

Bio­gen has con­found­ed the biotech world one more time.

In a stun­ning about-face, the com­pa­ny and its part­ners at Ei­sai say that a new analy­sis of a larg­er dataset on ad­u­canum­ab has re­stored its faith in the drug as a game-chang­er for Alzheimer’s and, af­ter talk­ing it over with the FDA, they’ll now be fil­ing for an ap­proval of a drug that had been giv­en up for dead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER